Design and evaluation of EphrinA1 mutants with cerebral protective effect
Abstract The activation of EphA2 receptor by its natural ligand EphrinA1 causes blood brain barrier dysfunction, and inactivation of EphA2 reduces BBB damage in ischemic stroke. Thus, EphA2 targeted antagonists may serve as neuroprotective agents. We engineered four mutants of EphrinA1, EM1, EM2, EM...
Guardado en:
Autores principales: | Yuanjun Zhu, Yuanqing Gao, Danping Zheng, Mengyang Shui, Kuai Yu, Xiaoyan liu, Yuan Lin, Li Su, Wenxing Yang, Yinye Wang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8334f8cc4c504f67a9c7b3affe658951 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
EphrinA1-targeted nanoshells for photothermal ablation of prostate cancer cells
por: Andre M Gobin, et al.
Publicado: (2008) -
Aggressive and recurrent ovarian cancers upregulate ephrinA5, a non-canonical effector of EphA2 signaling duality
por: Joonas Jukonen, et al.
Publicado: (2021) -
CIB1 synergizes with EphrinA2 to regulate Kaposi's sarcoma-associated herpesvirus macropinocytic entry in human microvascular dermal endothelial cells.
por: Chirosree Bandyopadhyay, et al.
Publicado: (2014) -
EphrinA2 regulates clathrin mediated KSHV endocytosis in fibroblast cells by coordinating integrin-associated signaling and c-Cbl directed polyubiquitination.
por: Dipanjan Dutta, et al.
Publicado: (2013) -
Neuroprotective effect of TAT-14-3-3ε fusion protein against cerebral ischemia/reperfusion injury in rats.
por: Yuanjun Zhu, et al.
Publicado: (2014)